Matthias Kretzler
Professor of Medicine University of Michigan
Seminars
Wednesday 18th March 2026
Panel Discussion: Data Sources in Nephrology Drug Development: Choosing Wisely, Mitigating Bias & Maximizing Impact
4:00 pm
- Sharing experience using different data sources (clinical trials, registries, EHRs, biobanks, biopsies) for drug development from discovery through regulatory approval and post-market
- Comparative strengths and limitations of each data source: e.g. trial data offers control and randomization; registry/EHR data offers large-scale, real-world generalizability but more noise; biopsy samples offer deep mechanistic insight but are invasive and limited in availability
- Strategies to handle missing, incomplete, or biased data: statistical techniques, data linkage, standard operating procedures for sample collection, dealing with confounders, ensuring representative sampling
- How to align data sourcing strategy with regulatory and payer requirements: the evidentiary standards, reporting, validation, transparency, reproducibility
- How to gain buy-in from diverse stakeholders (industry, federal, academic centers) for data sharing and collaboration, potentially identifying a convener or honest broker
- Discussing the extent to which professional medical societies (like ASN) and initiatives (like KHI) should be involved in data generation and evaluation
Tuesday 17th March 2026
Panel Discussion: Advancing Drug Development in Cardiovascular-Kidney-Metabolic (CKM) Syndrome
8:00 am
- Explore our evolving understanding of the pathophysiology linking cardiovascular, kidney and metabolic disorders
- Identify when and how overlapping CKM phenotypes can be leveraged to design more efficient clinical trials
- Discuss next steps in integrated drug development and regulatory frameworks for CKM components with shared mechanistic drivers
Wednesday 18th March 2026
Closing the Innovation Loop: Mechanistic Trials as a Tool for Precision Medicine in 2026
3:30 pm
- Integrating deep multiscalar data sets from biopsy cohort studies (NEPTUNE, KPMP, BEAT-DKD) has allowed to build a molecular map of the kidney in health and disease
- Mechanistic trials with entry and exit biomarkers and biopsies now allow to define treatment responses to experimental therapies
- First success in rare and common diseases will be presented
